middle.news
Cambium Bio advances Elate Ocular toward Phase 3 trial start
6:37pm on Wednesday 28th of October, 2026 AEDT
•
Biotechnology
Read Story
Cambium Bio advances Elate Ocular toward Phase 3 trial start
6:37pm on Wednesday 28th of October, 2026 AEDT
Key Points
Phase 3 technical batch completed and engineering batch commenced
Updated CAMOMILE-2 protocol received by the FDA
A$7.1 million placement awaits shareholder approval
A$1.194 million cash plus A$3.75 million undrawn RDTI facility
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Cambium Bio (ASX:CMB)
OPEN ARTICLE